Your browser doesn't support javascript.
loading
Corrigendum to "Phase 2, placebo-controlled clinical study of oral ganaxolone in PCDH19-clustering epilepsy" [Epilepsy Res. (2023) 191 107112].
Sullivan, Joseph; Gunning, Boudewijn; Zafar, Muhammad; Guerrini, Renzo; Gecz, Jozef; Kolc, Kristy L; Zhao, Yufan; Gasior, Maciej; Aimetti, Alex A; Samanta, Debopam.
Afiliação
  • Sullivan J; University of California San Francisco Weill Institute for Neurosciences, Benioff Children's Hospital, San Francisco, CA, USA.
  • Gunning B; Stichting Epilepsie Instellingen Nederland, Zwolle, the Netherlands.
  • Zafar M; Duke University School of Medicine, Durham, NC, USA.
  • Guerrini R; Meyer Children's Hospital, Florence, Italy.
  • Gecz J; Adelaide Medical School & Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia.
  • Kolc KL; University of New South Wales, Sydney, NSW, Australia.
  • Zhao Y; Marinus Pharmaceuticals, Inc., Radnor, PA, USA.
  • Gasior M; Marinus Pharmaceuticals, Inc., Radnor, PA, USA.
  • Aimetti AA; Marinus Pharmaceuticals, Inc., Radnor, PA, USA. Electronic address: aaimetti@marinuspharma.com.
  • Samanta D; University of Arkansas for Medical Sciences, Little Rock, AK, USA.
Epilepsy Res ; 203: 107342, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38480083
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article